parkinson's disease triple agonist glp-1 gip glucagon clinical trial Diabetes, obesity, and possible actions of Schematic illustration of monoagonists, dual

Berberine and GLP-1 are fundamentally different compounds targeting distinct metabolic pathways

Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making ...

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.